Navigation Links
Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
Date:5/7/2008

s

Forest Laboratories is a US-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in people's lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl-D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation; and Bystolic(TM) (nebivolol), a beta-adrenergic receptor blocking agent indicated for the treatment of hypertension. In addition to our growing product line, Forest also co-promotes the Daiichi Sankyo, Inc. product Azor(TM)* (amlodipine and olmesartan medoxomil), a calcium channel blocker and angiotensin receptor blocker combination product indicated for the treatment of hypertension. For more information, visit http://www.frx.com.

* Azor is a trademark of Daiichi Sankyo, Inc. and Campral is a registered trademark of Merck Sante s.a.s., a subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
2. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
3. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
6. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® in the ... that BioSpecifics, President, Tom Wegman , will present at ... Rodman & Renshaw 16 th ... ) Tuesday, September 9, 2014 at 9:10 a.m. ...
(Date:9/2/2014)... Sept. 2, 2014  Amgen (NASDAQ: ... of a Marketing Authorization Application (MAA) to ... centralized procedure for talimogene laherparepvec seeking approval ... that is regionally or distantly metastatic. Talimogene laherparepvec ... an intralesional injection that is designed to ...
(Date:9/2/2014)... SAN CARLOS, Calif. , Sept. 2, 2014 /PRNewswire/ ... a leader in synthetic biology, today announced that it ... Sanofi Chimie, a wholly owned subsidiary of Sanofi (EURONEXT: ... an enhanced production process for a specific family of ... manufacturing operations in France . This ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3
... WaferGen Biosystems, Inc. (OTCBB:WGBSE), a leading developer of state-of-the-art ... second quarter ended June 30, 2011."During the second quarter, ... commercialize the SmartChip Real-Time PCR System.  We accomplished that ... placement financing of $30.6 million in equity and debt ...
... RANCHO CORDOVA, Calif., Sept. 12, 2011 ThermoGenesis Corp. (NASDAQ: ... and services that process and store adult stem cells in ... quarter and all of fiscal 2011. For the ... $5.4 million, compared to $7.2 million in the fourth quarter ...
Cached Medicine Technology:WaferGen Reports Second Quarter 2011 Financial Results 2WaferGen Reports Second Quarter 2011 Financial Results 3WaferGen Reports Second Quarter 2011 Financial Results 4WaferGen Reports Second Quarter 2011 Financial Results 5WaferGen Reports Second Quarter 2011 Financial Results 6WaferGen Reports Second Quarter 2011 Financial Results 7WaferGen Reports Second Quarter 2011 Financial Results 8ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 2ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 3ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 4ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 5ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 6
(Date:9/2/2014)... (PRWEB) September 02, 2014 Anti-aging ... products and services such as anti-wrinkle treatments and ... based treatments, and breast augmentation becoming much sought ... by U.S.-based market intelligence firm Transparency Market Research, ... products will grow to USD 191.7 billion by ...
(Date:9/2/2014)... CITY, GA (PRWEB) September 02, 2014 Last ... whole new level with the launch of a luxurious line ... to announce that the SEA ISLAND COTTON Socks are joining ... compression level, giving more people the comfort of natural cotton ... COTTON Socks, they are surprised to find socks as soft ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Alliance Strategies ... and multi-channel email marketing is pleased to announce it ... Firearms & Freedom as well as ... represent more than one million concerned Americans who can ... , “We are honored to continue providing our ...
(Date:9/2/2014)... What happens when you are hospitalized, but your ... arrive at the office for follow-up care, but ... about your hospital stay? Missing or incomplete ... (PCPs) can contribute to poor experiences and lead ... study shows that implementing guidelines can improve hospitals, ...
(Date:9/2/2014)... health risks, including heart disease and diabetes, but University ... mitigate one often-overlooked risk: not buckling up in the ... Jacobson, a professor of computer science and of mathematics, ... a decrease in seatbelt usage. However, these effects can ... "Primary seatbelt laws lead to increased use of seatbelts," ...
Breaking Medicine News(10 mins):Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3Health News:Can data motivate hospital leaders to improve care transitions? 2Health News:Seatbelt laws encourage obese drivers to buckle up 2
... bit relaxed now. Genosis Inc, a US firm, has developed ... test has his and hers components a screening test ... the concentration of motile sperm, and a test for women ... ,The availability of the two-in-one test helps drive ...
... Depressed? Consider marriage as an option please, a pair of ... happier you could be after marriage . And never mind ... to benefit, claim Adrianne Frech, a sociology graduate student at ... ,They looked at a sample of 3,066 men and women ...
... WASHINGTON, D.C. A first-of-its-kind study presented at the 54th ... molecular imaging and nuclear medicine professionals , declares that ... tumor patients' response to treatment is a powerful predictor ... to the possibility that brain tumor patients may live ...
... of Preferred Provider Organizations (AAPPO) is launching a new ... care to those patients diagnosed with diabetes as ... An industry leader, AAPPO today kicked off its new ... take Action, Champion better care, and empower their patients ...
... announced today that HHS has awarded a contract for $500 ... manufacture and deliver 20 million doses of a next generation ... would be recommended in the event of a smallpox outbreak ... immune systems. The full supply of the vaccine will be ...
... Mental Health Services Administration (SAMHSA) today announced that ... three years to the state of Iowa ... The first year award is $400,000. This grant ... intervention and treatment services for youth suicide prevention ...
Cached Medicine News:Health News:Fertility Test at Home Possible With a New Kit 2Health News:Marriage Could Lift One Out of Depression, New Study 2Health News:Brain Tumor Patients Survival Depends on Predicting Treatment Responses Earlier 2Health News:AAPPO Launches ACT on Diabetes Initiative to Promote Improved Diabetes Care 2Health News:HHS Buys Next Generation Smallpox Vaccine 2Health News:HHS Buys Next Generation Smallpox Vaccine 3Health News:Iowa to Receive Grant Funding for Youth Suicide Prevention, Early Intervention 2
... Minimize Patient Trauma and Increase Staff Protection ... (10 Fr, 12 Fr, 14 Fr, 16 ... Suction Catheters with Contro-Vac Valves and DeLee ... potential for inflammation,during suctioning. Each catheter utilizes ...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Sterile, Coil Packed Suction Catheter Mini Tray with (2) Walleted SAFESKIN PURPLE NITRILE Latex-Free Exam Gloves...
Clear plastic sleeve envelopes a plastic suction catheter. Sleeve slides over exudate to reduce potential clinician contact....
Medicine Products: